SOHO 2025
Sep 3 - 6, 2025 | Houston, TX
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin LymphomaPF Caimi et al.
Poster
ARV-393, a PROTAC BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma ModelsA Van Acker et al.
Poster
ARV-393, a PROTAC BCL6 Degrader, in Preclinical Models of Diffuse Large B-cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular LymphomaA Van Acker et al.